Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
link https://doi.org/10.1056/NEJMoa2107715get_app2024-04-25. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile.pdf
account_box Jara, Alejandroaccount_box Undurraga, Eduardo A.account_box Gonzalez, Ceciliaaccount_box Paredes, Fabioaccount_box Fontecilla, Tomasaccount_box Jara, Gonzaloaccount_box Pizarro, Alejandraaccount_box Acevedo, Johannaaccount_box Leo, Katherineaccount_box Leon, Franciscoaccount_box Sans, Carlosaccount_box Leighton, Paulinaaccount_box Suarez, Pamelaaccount_box Garcia Escorza, Heribertoaccount_box Araos, Rafael
Comparte este registro
Inactivated SARS-CoV-2 Vaccine in Chile In a national prospective cohort study involving 10.2 million participants in Chile, the effectiveness of an inactivated SARS-CoV-2 vaccine, which had been developed in China and administered in two doses 28 days apart, was estimated. Effectiveness among fully immunized persons was estimated at 65.9% for Covid-19 and at 87.5% for hospitalization, 90.3% for ICU admission, and 86.3% for death.
Registro Sencillo
Registro Completo
| Autor | Jara, Alejandro Undurraga, Eduardo A. Gonzalez, Cecilia Paredes, Fabio Fontecilla, Tomas Jara, Gonzalo Pizarro, Alejandra Acevedo, Johanna Leo, Katherine Leon, Francisco Sans, Carlos Leighton, Paulina Suarez, Pamela Garcia Escorza, Heriberto Araos, Rafael |
| Título | Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile |
| Revista | NEW ENGLAND JOURNAL OF MEDICINE |
| ISSN | 0028-4793 |
| ISSN electrónico | 1533-4406 |
| Volumen | 385 |
| Número de publicación | 10 |
| Página inicio | 875 |
| Página final | 884 |
| Fecha de publicación | 2021 |
| Resumen | Inactivated SARS-CoV-2 Vaccine in Chile In a national prospective cohort study involving 10.2 million participants in Chile, the effectiveness of an inactivated SARS-CoV-2 vaccine, which had been developed in China and administered in two doses 28 days apart, was estimated. Effectiveness among fully immunized persons was estimated at 65.9% for Covid-19 and at 87.5% for hospitalization, 90.3% for ICU admission, and 86.3% for death. Background Mass vaccination campaigns to prevent coronavirus disease 2019 (Covid-19) are occurring in many countries; estimates of vaccine effectiveness are urgently needed to support decision making. A countrywide mass vaccination campaign with the use of an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine (CoronaVac) was conducted in Chile starting on February 2, 2021. Methods We used a prospective national cohort, including participants 16 years of age or older who were affiliated with the public national health care system, to assess the effectiveness of the inactivated SARS-CoV-2 vaccine with regard to preventing Covid-19 and related hospitalization, admission to the intensive care unit (ICU), and death. We estimated hazard ratios using the extension of the Cox proportional-hazards model, accounting for time-varying vaccination status. We estimated the change in the hazard ratio associated with partial immunization (>= 14 days after receipt of the first dose and before receipt of the second dose) and full immunization (>= 14 days after receipt of the second dose). Vaccine effectiveness was estimated with adjustment for individual demographic and clinical characteristics. Results The study was conducted from February 2 through May 1, 2021, and the cohort included approximately 10.2 million persons. Among persons who were fully immunized, the adjusted vaccine effectiveness was 65.9% (95% confidence interval [CI], 65.2 to 66.6) for the prevention of Covid-19 and 87.5% (95% CI, 86.7 to 88.2) for the prevention of hospitalization, 90.3% (95% CI, 89.1 to 91.4) for the prevention of ICU admission, and 86.3% (95% CI, 84.5 to 87.9) for the prevention of Covid-19-related death. Conclusions Our results suggest that the inactivated SARS-CoV-2 vaccine effectively prevented Covid-19, including severe disease and death, a finding that is consistent with results of phase 2 trials of the vaccine. (Funded by Agencia Nacional de Investigacion y Desarrollo and others.) |
| Derechos | acceso restringido |
| Agencia financiadora | Agencia Nacional de Investigacion y Desarrollo (ANID) Millennium Science Initiative Program Millennium Nucleus Center for the Discovery of Structures in Complex Data (MIDAS) Millennium Initiative for Collaborative Research in Bacterial Resistance (MICROB-R) Advanced Center for Chronic Diseases ANID Fondo de Financiamiento de Centros de Investigacion en Areas Prioritarias (FONDAP) Research Center for Integrated Disaster Risk Management ANID FONDAP |
| DOI | 10.1056/NEJMoa2107715 |
| Editorial | MASSACHUSETTS MEDICAL SOC |
| Enlace | |
| Id de publicación en Pubmed | MEDLINE:34233097 |
| Id de publicación en WoS | WOS:000672656600001 |
| Paginación | 10 páginas |
| Palabra clave | COVID-19 |
| Tema ODS | 03 Good Health and Well-being |
| Tema ODS español | 03 Salud y bienestar |
| Tipo de documento | artículo |